 |
Our Oncology business has been established worldwide
with standard therapy products for cancer, such as ENDOXAN
(cyclophosphamide), HOLOXAN
(ifosfamide), and UROMITEXAN
(mesna), for over 40 years. This product range has been steadily
expanded to include, ONKOTRONE
(mitoxantrone), BLEOMYCIN (Bleomycin) and others, some only available regionally.
The long-term objective is to help improve the treatment of cancer patients worldwide through the development, production, marketing, and sale of new, improved products in close cooperation with physicians, pharmacists, other care personnel, renowned scientists, organizations and associations, and with committed partner companies.
24th Annual Meeting of the International BFM Study Group
Kiel, May 17 - 19, 2013
Please visit the Baxter booth
4th International Congress on Leukemia Lymphoma Myeloma
Istanbul, May 22 - 25, 2013
Please visit the Baxter booth
EHA 2013 Stockholm,
June 14 - 16, 2013
Please visit the Baxter booth
12-ICML Lugano,
June 19 - 22, 2013
Please visit the Baxter booth
SIOP 2013 Hongkong,
September 25 - 28, 2013
Please visit the Baxter booth
ECCO 2013 Amsterdam,
September 27 - October 1, 2013
Please visit the Baxter booth
|
6th Edition of Drug Interactions available
1st Edition Selected Schedules in the Therapy of Childhood Cancers available
Recently published Highlights
Endoxan in Breast Cancer
Sales Folder Malignant Lymphomas
HOLOXAN, ENDOXAN
Essential components of effective chemotherapy regimens for malignant lymphomas.
Sales Folder Breast
ENDOXAN (Cyclophosphamide)
Essential and well-established cytotoxic
component of effective chemotherapeutic
regimens in the treatment of breast cancer.
Sales Folder Sarcomas
HOLOXAN, ENDOXAN
(Ifosfamide & Cyclophosphamide)
Essential and well-established cytotoxic components
of effective chemotherapeutic regimens for
the treatment of adult and pediatric sarcomas.
16th Edition of Selected Schedules available
16th Edition of Selected Schedules Chinese available
|
